CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality

Masatomo Taniguchi

Research output: Contribution to journalArticle

Abstract

The final goal of CKD-MBD (chronic kidney disease, mineral and bone disorder) is to reduce the risk of death in uremic patients. To achieve this objective, it is of importance to manage laboratory abnormalities, bone abnormalities, and vascular calcification appropriately. Many observation studies suggested that the good control of serum phosphate, calcium, and PTH concentration would lead to the lower risk of death. Fracture and vascular calcification would increase the risk for mortality. In addition, some randomized clinical trials have shown that the use of CKD-MBD related drugs, e.g. vitamin D, phosphate binder, might lead to reductions in the risk of death.

Original languageEnglish (US)
Pages (from-to)1078-1087
Number of pages10
JournalClinical calcium
Volume20
Issue number7
StatePublished - Jul 2010

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Vascular Calcification
Mortality
Risk Reduction Behavior
Vitamin D
Randomized Controlled Trials
Phosphates
Observation
Bone and Bones
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality. / Taniguchi, Masatomo.

In: Clinical calcium, Vol. 20, No. 7, 07.2010, p. 1078-1087.

Research output: Contribution to journalArticle

@article{e97c46ce7783415e98e0e51ce2f08767,
title = "CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality",
abstract = "The final goal of CKD-MBD (chronic kidney disease, mineral and bone disorder) is to reduce the risk of death in uremic patients. To achieve this objective, it is of importance to manage laboratory abnormalities, bone abnormalities, and vascular calcification appropriately. Many observation studies suggested that the good control of serum phosphate, calcium, and PTH concentration would lead to the lower risk of death. Fracture and vascular calcification would increase the risk for mortality. In addition, some randomized clinical trials have shown that the use of CKD-MBD related drugs, e.g. vitamin D, phosphate binder, might lead to reductions in the risk of death.",
author = "Masatomo Taniguchi",
year = "2010",
month = "7",
language = "English (US)",
volume = "20",
pages = "1078--1087",
journal = "Clinical calcium",
issn = "0917-5857",
publisher = "Iyaku (Medicine & Drug) Journal Co",
number = "7",

}

TY - JOUR

T1 - CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality

AU - Taniguchi, Masatomo

PY - 2010/7

Y1 - 2010/7

N2 - The final goal of CKD-MBD (chronic kidney disease, mineral and bone disorder) is to reduce the risk of death in uremic patients. To achieve this objective, it is of importance to manage laboratory abnormalities, bone abnormalities, and vascular calcification appropriately. Many observation studies suggested that the good control of serum phosphate, calcium, and PTH concentration would lead to the lower risk of death. Fracture and vascular calcification would increase the risk for mortality. In addition, some randomized clinical trials have shown that the use of CKD-MBD related drugs, e.g. vitamin D, phosphate binder, might lead to reductions in the risk of death.

AB - The final goal of CKD-MBD (chronic kidney disease, mineral and bone disorder) is to reduce the risk of death in uremic patients. To achieve this objective, it is of importance to manage laboratory abnormalities, bone abnormalities, and vascular calcification appropriately. Many observation studies suggested that the good control of serum phosphate, calcium, and PTH concentration would lead to the lower risk of death. Fracture and vascular calcification would increase the risk for mortality. In addition, some randomized clinical trials have shown that the use of CKD-MBD related drugs, e.g. vitamin D, phosphate binder, might lead to reductions in the risk of death.

UR - http://www.scopus.com/inward/record.url?scp=77957652766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957652766&partnerID=8YFLogxK

M3 - Article

C2 - 20585187

AN - SCOPUS:77957652766

VL - 20

SP - 1078

EP - 1087

JO - Clinical calcium

JF - Clinical calcium

SN - 0917-5857

IS - 7

ER -